Lawsuit Help Desk

Beovu Lawsuits and Settlements

Did you or your loved one take Beovu to treat your wet age-related macular degeneration (AMD)? Were you or your loved one later diagnosed with retinal vasculitis, vascular occlusion, vision loss, or blindness?

If yes, then there is a real likelihood you would qualify for a Beovu lawsuit and settlement opportunity. 

Will your leading mass torts
firms take my case?

Contact us to find out (We’ll get back to you the same day)

"*" indicates required fields

I represent, understand and agree that: 1) I am 18 years of age or older; 2) I have read and agree to Lawsuithelpdesk.com’s Terms of Service, Privacy Policy, that the representations here are Paid Attorney Advertising, and additional legal disclaimers herein (if any); 3) submitting this form does not create an attorney-client relationship; 4) I am not already represented by an attorney for this matter; and 5) I consent to be contacted under the Terms and Conditions of Contact in order to discuss my legal options, so that I may obtain legal representation.

Why Are Beovu Lawsuits Being Filed?

Novartis Pharmaceuticals Corporation developed Beovu (brolucizumab), which the FDA approved in October 2019 to treat wet age-related macular degeneration (wAMD). This is a common and serious eye condition. The drug operates by blocking the activity of vascular endothelial growth factor (VEGF) to reduce macular swelling and improve vision. Also, it produces an anti-inflammatory effect to slow or stop macular degeneration. Basically, Beovu is administered as an injection into the eye, but it can be used with other treatments. However, many users of Beovu have experienced severe side effects, such as retinal vasculitis, vascular occlusion, vision loss, and blindness.

Maculopathy is a general category for several conditions that affect the macula, a small area in the center of the retina located at the back of the eye, consequently causing vision loss and blindness. Also, macular degeneration is a type of maculopathy that is one of the most common causes of vision loss among people over 40 years old. It damages the tiny light-sensitive cells in the macula which leads to progressive vision distortion and loss.

Additionally, Age-Related Macular Degeneration, caused by aging cells that break down and damage the macula, is the most common cause of macular degeneration. In the United States alone, around 8 million people suffer from this condition.

Generally, there are two types of Age-Related Macular Degeneration: wet and dry maculopathy. On the one hand, dry maculopathy, the most common form of macular degeneration, is caused by thinning of the macula due to age-related changes. Eventually, it leads to gradual vision loss, affecting central and color vision first. Addressing it includes nutritional supplements, lifestyle modifications, and regular monitoring by an ophthalmologist. Further, laser surgery may also be an option in severe cases.

Contrarily, wet maculopathy occurs when abnormal blood vessels grow under the retina. This results in a leaking fluid or blood that causes further macular damage. This progresses more quickly than dry maculopathy because it leads to rapid vision loss that often requires longer treatment. Treatment involves anti-VEGF drug injections, laser surgery, or photodynamic therapy.

Overall, macular degeneration is not a reversible condition. Proper management and early diagnosis can reduce its severity and ultimately prevent vision loss. Therefore, regular eye exams and lifestyle changes such as a healthy diet and exercise are helpful preventive measures. With good medical care and early diagnosis, macular degeneration can be managed or prevented.

On October 7, 2019, the U.S. Food and Drug Administration (FDA) authorized Beovu for the treatment of wet age-related macular degeneration. However, the common side effects associated with Beovu include cataracts (clouding of the lens in the eye), conjunctival hemorrhage (bleeding at the front portion of the eyes), visual acuity, and vitreous floaters (spots in the vision). Furthermore, medical research has revealed that the drug can cause very serious maculopathy side effects, including vascular occlusion and retinal vasculitis, which can lead to vision loss and even blindness.

Novartis’ Own Findings (2020)

In 2020, Novartis completed their initial safety review on Beovu. This is their FDA-approved biologic for wet age-related macular degeneration. They found that a number of patients can develop severe adverse reactions, such as retinal vasculitis or retinal blockage leading to profound visual loss. Thereafter, Novartis added these potential side effects to the drug’s warning label.

Lin and Browning, Journal of Ophthalmology (2021)

In 2021, Lin and Browning performed a systematic review of existing research and found that a significant number of patients experienced vascular occlusion or retinal vasculitis after receiving Beovu treatment. Consequently, 24 more studies were conducted. The findings provide that 1.2% developed vascular occlusion, while 4.6% of patients experienced retinal vasculitis.

Needless to say, these scientific findings have negative implications for patients currently undergoing or considering undergoing Beovu treatment for wet age-related macular degeneration. These studies alarmingly suggest that there is a high risk of developing retinal vasculitis or vascular occlusion, both of which can lead to vision loss.

Journal of the American Medical Association (JAMA) Ophthalmology (2020)

In 2020, JAMA Ophthalmology Journal published a study on the side effects of Beovu. Similarly, it was found that 10 out of 17 patients developed vascular occlusion and/or retinal vasculitis after receiving Beovu treatment. Ultimately, these side effects could lead to vision loss. The researchers highlighted the importance of close monitoring of patients receiving Beovu treatment for signs of these side effects.

New England Journal of Medicine Study (2021)

In 2021, New England Journal of Medicine published a randomized trial where the researchers found that patients who received Beovu had a higher incidence of retinal vasculitis compared to those who received a different treatment. Evidently, the study is highly reliable for using a randomized, double-masked, and multicenter trial among 1,218 patients with wet AMD for 52 consecutive weeks.

Therefore, these studies show alarming implications for patients currently receiving or considering undergoing a Beovu treatment for wet age-related macular degeneration. In sum, the studies relate Beovue treatment with significant risks of developing retinal vasculitis or vascular occlusion leading to vision loss.

What is the Current Status of Beovu Lawsuits?

Currently, the number of lawsuits is increasing, but they do not currently warrant multidistrict litigation (MDL). Over the past three years, patients who received Beovu treatment have filed lawsuits against the drug’s manufacturer. Their claims are based on the company’s negligence in thoroughly inquiring about the negative effects of the injection that was marketed to treat wet age-related macular degeneration. Also, the company was alleged to have withheld information from both users and the medical community about the possibility that Beovu could cause long-term eye damage.

One of the first lawsuits in the U.S. District Court for the Northern District of Arkansas was filed by Barbara Frye on June 24, 2022. The plaintiff had undergone a Beovu injection in January 2020 and was diagnosed with retinal vascular occlusion, which limits blood flow to the retina, just a few months later in March 2020. She claims that Beovu was responsible for her eye damage. Novartis, the manufacturer of Beovu, insisted that Beovu’s ocular irritation rates were minimal hence the safety of its new medicine.

Meanwhile, Novartis argued for federal preemption in response to Frye’s lawsuit, maintaining that the prior FDA approval of the label preempts state law-based failure to warn allegations. However, on September 19, 2022, U.S. District Judge Kristine Baker of the U.S. District Court for the Eastern District of Arkansas rejected the preemption defense of Novartis and approved the continuation of the Beovu action. She denied Novartis’ request to dismiss the case. The court was not convinced by the pharmaceutical company’s claims and reasoning at this point in the dispute. As long as Beovu was on the market, Novartis was always in charge of the substance of its labeling, including the label’s design and warnings. If Novartis won the case brought by Ms. Frye, it could have a major impact on other consumers who were left with long-term eye damage from Beovu.

Currently, the number of lawsuits is increasing, but they do not currently warrant multidistrict litigation (MDL). Over the past three years, patients who received Beovu treatment have filed lawsuits against the drug’s manufacturer. Their claims are based on the company’s negligence in thoroughly inquiring about the negative effects of the injection that was marketed to treat wet age-related macular degeneration. Also, the company was alleged to have withheld information from both users and the medical community about the possibility that Beovu could cause long-term eye damage.

One of the first lawsuits in the U.S. District Court for the Northern District of Arkansas was filed by Barbara Frye on June 24, 2022. The plaintiff had undergone a Beovu injection in January 2020 and was diagnosed with retinal vascular occlusion, which limits blood flow to the retina, just a few months later in March 2020. She claims that Beovu was responsible for her eye damage. Novartis, the manufacturer of Beovu, insisted that Beovu’s ocular irritation rates were minimal hence the safety of its new medicine.

Meanwhile, Novartis argued for federal preemption in response to Frye’s lawsuit, maintaining that the prior FDA approval of the label preempts state law-based failure to warn allegations. However, on September 19, 2022, U.S. District Judge Kristine Baker of the U.S. District Court for the Eastern District of Arkansas rejected the preemption defense of Novartis and approved the continuation of the Beovu action. She denied Novartis’ request to dismiss the case. The court was not convinced by the pharmaceutical company’s claims and reasoning at this point in the dispute. As long as Beovu was on the market, Novartis was always in charge of the substance of its labeling, including the label’s design and warnings. If Novartis won the case brought by Ms. Frye, it could have a major impact on other consumers who were left with long-term eye damage from Beovu.

Currently, the Beovu visual injury and blindness cases against Novartis are in the initial stages.

As a result, no recorded settlements have been published.

However, we have listed below our estimates for the settlement amounts. But please note that these estimates should be viewed with caution to prevent false hopes. The ultimate amounts will depend on the injury suffered.

Please note that the degree of the damage varies between cases, from partial sight loss to total blindness. Since the claims are still in the early stages of the proceedings, it is difficult to determine specific settlement amounts. Nevertheless, our leading legal experts recommend that settlement amounts could range as follows: those claiming high-level vision loss (above 80%) could claim between $600,000 and $900,000; mid-level vision loss (40% – 80%) may be able to negotiate up to $550,000; and those with low-level vision loss (below 40%) may be awarded up to $150,000.

How can I tell if I qualify for a beovu lawsuit?

If you have received Beovu injections and experienced any of these adverse side effects, you should contact us immeditately: 

  • Retinal vasculitis
  • Retinal vascular occlusion
  • Vision loss, or
  • Blindness
woman recovering in hospital who's filed a Beovu lawsuit
weighing the benefits of Beovu lawsuit

What are my legal fees if your lawyers take my beovu lawsuit?

If you qualify, the legal representation will be an entirely contingent fee, which is good news for you!

Basically, a contingent fee means that the law firm representing you will pay for all fees and expenses related to the legal proceedings. In other words, you don’t have to pay anything. Instead, the settlement or award you get will be used to cover your legal fees.

And in the unlikely event that the matter is not resolved or won, what happens? You won’t have to pay anything out-of-pocket because the law firm that is representing you will take on all of that risk.

How much can I recover from my Beovu lawsuit?

Although it is impossible to ascertain the amounts, our Beovu lawsuit experts suggest the following ranges:

$600,000 to $900,000 (high-level vision loss or above 80%)

$400,000 to $550,000 (mid-level vision loss or 40% – 80%)

$40,000 to $150,000 (low-level vision loss or below 40%)

celebrating a Beovu Lawsuit settlement
lawyer counseling about Beovu lawsuit

If I Qualify, Do I Owe Lawsuit Help Desk Or Your Lawyers?

Absolutely not.

Basically, if you qualify, you are under no obligation to us.

Instead, our Beovu lawsuit lawyers will go over the retainer agreement with you.

How long do I have to file my beovu lawsuit?

File it immediately!

It is very important to secure legal representation as soon as possible. Basically, statutes of limitations and repose are key factors in determining whether or not you can pursue a successful claim. In other words, time is of the essence. Clearly, delays could prevent you from recovering much-needed compensation for yourself and your family.

Our Beovu lawsuit lawyers will quickly check on the statutes of limitations and repose applicable in your state.

So, do not miss any opportunities for settlement. Act now!

Generally, each state has its own statutes of limitations (SOL) and statutes of repose for each type of damage (SOR). Basically, these statutes prevent lawsuits from being filed or enforced after preset time limits. So, after these periods pass, a lawsuit will be dismissed. Hence, you will collect nothing.

Statutes of limitations provide the maximum length of time that plaintiffs have to file their claim from the date of an alleged offense to file a lawsuit. Furthermore, statutes of repose are stricter since these can terminate a right to sue after a predetermined amount of time has passed, regardless of whether the cause of action has accrued.

So, talk to our Beovu lawsuit lawyers now!

Generally, there is a number of scientific evidence linking Beovu to retinal vasculitis, retinal occlusion, and partial and full vision loss.

However, this is not the typical case. It may take years for scientific research to show a connection between the offending drug or other cause and the patient’s symptoms. 

But once known, the injured plaintiff must file the complaint as soon as possible. Basically, the period for statutes of limitation already commenced. Regrettably, in states with offensive statutes of repose, it may already be too late to file the case.

So, be sure to reach out to us because our Beovu lawsuit lawyers ASAP.

Basically, you cannot get a settlement if your Beovu lawsuit has not been filed first. Simple!

However, know that large defendants do not like to affect individual settlements except at low dollar values. Despite the harm caused, they consider individual settlements a drain of their time and resources. 

So, talk to our leading Beovu lawsuit lawyers today. They will honestly assess your case for you!

lawyers sprinting to file a Beovu lawsuit
client contacts lawyer about Beovu lawsuit

What are my next steps for filing and settling my Beovu lawsuit?

Be sure to contact us ASAP if you want to feel at ease!

Also, save all the paperwork that our lawyers will require as proof starting right now. This includes any prescriptions, receipts, medical bills, reports, tests, and diagnoses, as well as any other paperwork that relates to your Beovu lawsuit.

But don’t stress out. Once our Beovu lawsuit lawyers accept your case, they will contact the doctors, labs, hospitals, and pharmacies.

So, contact us today and talk to our Beovu lawsuit lawyers.

Why Lawsuit Help Desk is Different

Unlike most legal assistance websites, we do not act like third-party middlemen. Instead, we provide you immediate access to top 1%, nationally renowned mass torts attorneys with deep knowledge in Beovu litigation. It is these leading lawyers who decide whether you qualify and if your case has merit. We will be forthright and honest with you.

Our mission is to inform the public and provide direct access to leading lawyers in the world of mass torts. 

We are not that robotic and annoying call center. We respect your time and hence will not hand you off, or give you the run-around. 

We are not a marketing firm. Also, there will be no robocalls from us. If you receive an email, it is sent with the intent of providing helpful information, such as case status and ongoing research. No spammy emails! We are here to help, not badger you.

What ultimately sets us apart is our team of active and dedicated lawyers. Mass torts settlements could go in the hundreds of thousands and millions. Therefore, you need expert advice. Do you really want to get that from a marketing or social media expert, a lifestyle coach, a psychologist, or an influencer? In other words, we are not parroting talking points. Our leading lawyers know what they are talking about. 

In fact, Lawsuit Help Desk was founded by Cameron Tousi, a leader and visionary in the world of complex litigation. With decades of experience and expertise, he has received the highest distinctions in peer reviews and awards from America’s leading legal publications. If you’d like to speak with Cameron, just let us know, and we’ll be happy to assist you! 

Monthly Status Updates: Novartis Beovu Lawsuits

Currently, the Frye case is still pending as of March 2023.

Apparently, there are no significant rulings yet on the case. A number of Beovu lawsuits in the U.S. remain pending as well.

Currently, Novartis argued that federal preemption was applicable in the Frye case. Specifically, Novartis asserted that claims of failure to warn based on state law are preempted by the label’s earlier FDA clearance.

Novartis’ motion dismissed

Oftentimes, this type of legal defense strategy frequently succeeds. If the drug company had prevailed here, it might have had a substantial impact on other Beovu lawsuit plaintiffs. In other words, granting such a motion will bar recovery from those are pursuing claims against Novartis.

Preemption defense

Fortunately, U.S. District Judge Kristine Baker of the Eastern District of Arkansas issued a decision on September 19, 2022 dismissing the preemption defense. Hence, the dismissal allows for the continuation of the Beovu lawsuits. Judge Baker wrote that the defendants failed to persuade the court. Hence, it cannot simply evade responsibility for its label’s layout necessary warnings by raising the preemption defense.

On June 24, 2022, Barbara Frye filed one of the first Beovu lawsuits in the U.S. District Court for the Northern District of Arkansas.

Basically, it was in January 2020 that Frye received an injection of Beovu. Thereafter, in March 2020, she was diagnosed with retinal vascular occlusion—a condition resulting from restricted blood flow to her retina.

Also, Frye alleges that this condition was caused by Beovu. Even though Novartis updated their warning label in June 2020, Novartis had previously maintained that Beovu does not cause ocular side effects.

Basically, the Beovu lawsuits commenced in early 2021.

Similarly, the Lawsuit Help Desk Beovu lawsuit lawyers handle Beovu claims and continue to assess inquiries for eligibility.  Beovu lawsuits, like other mass torts and class action claims, are usually handled on a contingent fee basis. In other words, these are on a no-win, no-fee basis.

So, clients will not owe the law firms any upfront fees for legal representation.

Currently, Novartis released more details regarding its safety study of Beovu around mid-November 2020.

Basically, they discovered that patients with Beovu who had previously experienced intraocular inflammation or vascular occlusion were at a higher risk of developing retinal vasculitis or retinal vascular occlusion.

Hence, all Beovu-using individuals, according to Novartis, were at a risk rate of roughly 4%.

At the moment, the American Academy of Ophthalmology published a study on Beovu-related retinal vasculitis and intraocular inflammation (IOI).

In sum, according to the study’s findings, the treatment can result in visual loss.

Retinal vasculitis

Also, they looked at Beovu patients with retinal vasculitis. After 25 days following the final Beovu dose, the researchers discovered a reduction in their mean visual acuity.

Therefore, this indicates that the difficulties brought on by Beovu are serious and could lead to eyesight loss that is permanent.

At this time, the FDA authorized a revised “black box” warning label for Beovu in June 2020.

Moreover, the new Beovu warning label now includes potential risk of retinal vasculitis and a retinal vascular occlusion.

However, there are currently no intentions for a Beovu recall. Nonetheless, the drug’s use has been essentially discontinued due to safety concerns.

Recently, two ophthalmologists claimed in the May 2020 issue of the American Journal of Ophthalmology that Beovu use ought to be discontinued.

Basically, they claim that it should be discontinued until experts determine how it is connected to retinal vasculitis.

ASRS refusal

Also, they said that ASRS and Novartis did not go far enough when it refused to ban Beovu injections.

Moreover, ophthalmologists clarified that other wet AMD medications are not linked with retinal vasculitis. Thus, wet AMD patients could safely be treated under a different treatment.

On April 8, 2020, less than two months after the review’s conclusion, Novartis made the announcement.

Basically, they examined patients with Beovu instances with significant vision loss, retinal artery blockage, and vasculitis.

Safety warning

Also, Novartis admitted that at least some Beovu patients may have retinal vasculitis or retinal occlusion with significant vision loss based on its assessments.

Additionally, they disclosed that they will be adding these issues to Beovu’s safety and warning literature.

At this point, Novartis disclosed that Beovu would be the subject of an external safety evaluation by the end of February 2020.

Further, the American Society of Retina Specialists (ASRS) had expressed concern about its negative effects days before to this publication.

Retinal vasculitis

Interestingly, ASRS recorded 14 cases of vasculitis linked to Beovu. Further, occlusive retinal vasculitis was seen in 11 of them.

Notwithstanding the release of the safety evaluation, Novartis openly continued to assure the public of Beovu’s safety.

News & Articles

Beovu Lawsuits and Settlements: A Comprehensive Overview

Beovu Lawsuits and Settlements: A Comprehensive Overview

Beovu Lawsuits and Settlements: A Comprehensive Overview

Beovu (brolucizumab-dbll) is an FDA-approved prescription medication used to treat wet age-related macular degeneration (AMD). However, this drug has been linked to severe vision loss caused by retinal vasculitis and retinal vascular occlusion. As a result, numerous lawsuits have been filed against Novartis, the manufacturer of Beovu, with plaintiffs alleging that the company failed to adequately warn patients and doctors about the potential vision side effects.

As of July 6, 2023, there have been no trials or court-approved settlements in the Beovu lawsuits. These cases are currently being heard individually in various courts across the country, with some of the earliest lawsuits filed in Arkansas and Nebraska. Lawyers are still accepting cases, and so far, Novartis has not been successful in dismissing claims based on preemption.

In one particular case involving Barbara Frye and Edith A. Harris, both plaintiffs voluntarily dismissed their claims. Harris's case was dismissed with prejudice in March 2023, and Frye filed a stipulation of dismissal with prejudice in the same month. The reasons behind their decisions to dismiss are not disclosed in court documents. However, in September 2022, Novartis's motion to dismiss Frye's Beovu vision lawsuit case was denied. The trial was initially scheduled for February 2023 but has been rescheduled multiple times and is now set for April 2024.

The allegations made by the plaintiffs in the Beovu lawsuits revolve around the lack of warnings for occlusive retinal vasculitis on the drug's prescribing information until June 2020. Lawyers argue that Novartis put patients at risk of vasculitis, occlusive retinal vasculitis, and blindness by not providing adequate warnings.

In February 2020, the American Society of Retina Specialists (ASRS) reported 14 cases of vasculitis in patients who took Beovu, with 11 cases involving occlusive retinal vasculitis. By the following month, the number of cases increased to 25, with 21 of them involving occlusion.

Novartis has maintained that Beovu is safe and effective. In June 2020, the company referred to these reports as "rare post-marketing safety events." However, after reviewing the information from the ASRS, Novartis announced in April 2020 that it would evaluate reports of severe vision loss and vascular issues associated with Beovu. The drug maker acknowledged the confirmed safety signal of rare adverse events of retinal vasculitis and/or retinal vascular occlusion that may lead to severe vision loss.

Although the FDA approved a label change in February 2020 to include additional safety information regarding retinal vasculitis and retinal vascular occlusion, neither Novartis nor the FDA has issued a Beovu recall.

The potential side effects of Beovu listed in the prescribing insert include blurred vision, cataracts, eye hemorrhage, and blood vessel inflammation in the back of the eye. However, the original prescribing label did not include warnings about retinal vasculitis and retinal occlusion.

In August 2020, a case study was reported on a 77-year-old woman who experienced acute visual acuity loss in her right eye after taking two doses of Beovu. She was diagnosed with retinal vasculitis. Notably, she did not experience any eye inflammation when using other drugs for wet age-related macular degeneration.

The Beovu lawsuits are a complex and ongoing legal battle. Plaintiffs argue that Novartis failed to adequately warn about the potential vision side effects of Beovu, which resulted in severe vision loss for some patients. These cases are being pursued, indicating a belief in the validity of the claims against Novartis. As the litigation continues, it is important to stay updated on the developments surrounding these lawsuits and the potential settlements that may arise in the future.

Read more here

PAID ATTORNEY ADVERTISEMENT: This Website is a group advertisement. It is not a lawyer referral service. Lawsuithelpdesk.com is owned and operated by Awon Holdings LLC and is not a law firm. We connect people to legal service and there is no charge to be connected with an attorney. You are under no obligation to retain any services of those connected through our website. We try our best to keep things fair and balanced to help you make the best choice for you. This information does not constitute legal or medical advice and it should not be relied upon as such. Results are not guaranteed and past performance is not an indication of future success. Always consult with your doctor before modifying your medication or regular medical regimen.

Copyright © 2023 www.lawsuithelpdesk.com - All Rights Reserved